Quantum-Si, an end-to-end proteomics solutions provider, went public via a SPAC merger with HighCape Capital Acquisition, a healthcare-focused SPAC sponsored by leading healthcare growth equity investment firm HighCape Capital, in a $1.5bn. The transaction supported by a $425m PIPE with participation from investors including Foresite Capital, Eldridge, ARK Invest, Glenview Capital Management, and Redmile Group. “I am thrilled with the completion of this business combination, which will power the commercialization of our technology to disrupt the rapidly growing proteomics market. Having been at the forefront of next-generation DNA sequencing, it is very fitting that our team is also on the cusp of making next-generation protein sequencing a reality. Similar to the introduction of next-gen DNA sequencing, our proteomics technology has the potential to enable exponential advances in drug discovery, academic research, and diagnostics," Jonathan Rothberg, Quantum-Si Founder and Executive Chairman.